AML MRD Detection Assay

Next-generation sequencing (NGS) is a powerful emerging method for detecting residual acute myeloid leukemia (AML) after treatment. However, current methods produce an abundance of sequencing errors which obscure low-frequency leukemia-defining mutations.

The TwinStrand Duplex Sequencing™ AML MRD assay is orders of magnitude more sensitive and specific than other NGS-based MRD assays, offering unprecedented opportunities for clinical research and drug development.

>100-fold higher resolution than other error-corrected NGS methods
The 29 gene, 58kb panel encompasses loci mutated in 90%-95% of adult AML patients
Assay enables sub-1/10,000 limit of detection anywhere in target region

Download Data Sheet

Duplex Sequencing MRD Technical Performance

The TwinStrand Duplex Sequencing AML MRD assay was used to sequence a serially-diluted mixture of AML mutation-containing DNA to a duplex depth >1,000,000x. Target clones were identified to levels <1/100,000 with 100% sensitivity and specificity.

Download Data Sheet

Panel Overview

The AML panel encompasses the whole coding region or hotspots in 29 genes recurrently mutated in Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Clonal Hematopoiesis (CHIP).